Schoepp D - Search Results

1

Translating glutamate: from pathophysiology to treatment.

Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM. Javitt DC, et al. Among authors: schoepp d. Sci Transl Med. 2011 Sep 28;3(102):102mr2. doi: 10.1126/scitranslmed.3002804. Sci Transl Med. 2011. PMID: 21957170 Free PMC article. Review.

2

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.

Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ. Schoepp DD, et al. Stress. 2003 Sep;6(3):189-97. doi: 10.1080/1025389031000146773. Stress. 2003. PMID: 13129812 Free article. Review.

3

Glutamate-hypothalamic-pituitary-adrenal axis interactions: implications for mood and anxiety disorders.

Mathew SJ, Coplan JD, Schoepp DD, Smith EL, Rosenblum LA, Gorman JM. Mathew SJ, et al. Among authors: schoepp dd. CNS Spectr. 2001 Jul;6(7):555-6, 561-4. doi: 10.1017/s1092852900002091. CNS Spectr. 2001. PMID: 15573019

4

Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo.

Waterhouse RN, Schmidt ME, Sultana A, Schoepp DD, Wheeler WJ, Mozley PD, Laruelle M. Waterhouse RN, et al. Among authors: schoepp dd. Nucl Med Biol. 2003 Feb;30(2):187-90. doi: 10.1016/s0969-8051(02)00423-7. Nucl Med Biol. 2003. PMID: 12623118

5

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Witkin JM, et al. Among authors: schoepp dd. CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. doi: 10.2174/187152707780363302. CNS Neurol Disord Drug Targets. 2007. PMID: 17430147 Review.

6

Alzheimer's disease research and development: a call for a new research roadmap.

Feldman HH, Haas M, Gandy S, Schoepp DD, Cross AJ, Mayeux R, Sperling RA, Fillit H, van de Hoef DL, Dougal S, Nye JS; One Mind for Research and the New York Academy of Sciences. Feldman HH, et al. Among authors: schoepp dd. Ann N Y Acad Sci. 2014 Apr;1313:1-16. doi: 10.1111/nyas.12424. Ann N Y Acad Sci. 2014. PMID: 24754377

7

Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats.

Clark M, Johnson BG, Wright RA, Monn JA, Schoepp DD. Clark M, et al. Among authors: schoepp dd. Pharmacol Biochem Behav. 2002 Sep;73(2):339-46. doi: 10.1016/s0091-3057(02)00848-1. Pharmacol Biochem Behav. 2002. PMID: 12117588

8

Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.

Dominguez C, Prieto L, Valli MJ, Massey SM, Bures M, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD, Monn JA. Dominguez C, et al. Among authors: schoepp dd. J Med Chem. 2005 May 19;48(10):3605-12. doi: 10.1021/jm040222y. J Med Chem. 2005. PMID: 15887967

9

5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740.

Marek GJ, Wright RA, Schoepp DD. Marek GJ, et al. Among authors: schoepp dd. Neurosci Lett. 2006 Aug 7;403(3):256-60. doi: 10.1016/j.neulet.2006.05.021. Epub 2006 Jun 6. Neurosci Lett. 2006. PMID: 16759803

10

Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist.

Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Monn JA. Schoepp DD, et al. Naunyn Schmiedebergs Arch Pharmacol. 1998 Aug;358(2):175-80. doi: 10.1007/pl00005240. Naunyn Schmiedebergs Arch Pharmacol. 1998. PMID: 9750002

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters